GPC1 and familial pancreatic carcinoma: GPC1+ crExos demonstrated 100% sensitivity and specificity across all pancreatic cancer stages (in situ, stage I, and stages II–IV), highlighting their potential as biomarkers throughout the progression of pancreatic cancer and their application in early detection [86].